Suppliers and packagers for estazolam

estazolam

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Dr Reddys Labs Sa	ESTAZOLAM	estazolam	TABLET;ORAL	074921	ANDA	Dr. Reddy's Labratories Inc.	75907-028-01	100 TABLET in 1 BOTTLE, PLASTIC (75907-028-01)	2024-02-15
Dr Reddys Labs Sa	ESTAZOLAM	estazolam	TABLET;ORAL	074921	ANDA	Dr. Reddy's Labratories Inc.	75907-029-01	100 TABLET in 1 BOTTLE, PLASTIC (75907-029-01)	2024-02-15
Novitium Pharma	ESTAZOLAM	estazolam	TABLET;ORAL	074826	ANDA	Novitium Pharma LLC	70954-480-10	100 TABLET in 1 BOTTLE (70954-480-10)	2021-04-08
Novitium Pharma	ESTAZOLAM	estazolam	TABLET;ORAL	074826	ANDA	Novitium Pharma LLC	70954-481-10	100 TABLET in 1 BOTTLE (70954-481-10)	2021-04-08
Watson Labs	ESTAZOLAM	estazolam	TABLET;ORAL	074818	ANDA	Actavis Pharma, Inc.	0591-0744-01	100 TABLET in 1 BOTTLE, PLASTIC (0591-0744-01)	1997-10-01
Watson Labs	ESTAZOLAM	estazolam	TABLET;ORAL	074818	ANDA	Actavis Pharma, Inc.	0591-0745-01	100 TABLET in 1 BOTTLE, PLASTIC (0591-0745-01)	1997-10-01

ESTAZOLAM SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report details the key suppliers and manufacturing landscape for Estazolam, a benzodiazepine medication prescribed for the short-term treatment of insomnia. The analysis focuses on active pharmaceutical ingredient (API) manufacturers, finished dosage form (FDF) producers, and relevant market dynamics impacting the Estazolam supply chain.

WHO ARE THE PRIMARY API MANUFACTURERS FOR ESTAZOLAM?

The production of Estazolam's active pharmaceutical ingredient is concentrated among a limited number of specialized chemical manufacturers. These entities are critical to the upstream supply chain, providing the foundational compound for all Estazolam-based medications.

• Teva Pharmaceutical Industries Ltd.: Teva is a significant player in the generic pharmaceutical market and is known to produce Estazolam API. The company operates a global network of manufacturing facilities.
• Accord Healthcare Ltd.: Accord Healthcare is a UK-based pharmaceutical company with manufacturing capabilities that include API production for various therapeutic classes.
• Sun Pharmaceutical Industries Ltd.: Sun Pharma, one of the largest generic pharmaceutical companies globally, also manufactures Estazolam API, leveraging its extensive chemical synthesis expertise.
• Amneal Pharmaceuticals LLC: Amneal is a US-based manufacturer that has been involved in the production of generic APIs, including those for benzodiazepines.

These manufacturers adhere to strict Good Manufacturing Practices (GMP) mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). API production requires advanced chemical synthesis processes, stringent quality control, and robust supply chain management to ensure purity, potency, and consistency.

WHICH COMPANIES MANUFACTURE FINISHED DOSAGE FORMS (FDFS) OF ESTAZOLAM?

The finished dosage forms of Estazolam, typically oral tablets, are manufactured by pharmaceutical companies that formulate the API into a marketable product. This stage involves blending the API with excipients, granulation, tableting, and packaging.

• Prometheus Laboratories Inc. (a Nestlé Health Science company): While primarily known for diagnostic testing, Prometheus has historically been associated with the distribution and marketing of Estazolam under various brand names.
• Teva Pharmaceuticals: Beyond API production, Teva also formulates and markets finished Estazolam tablets.
• Sun Pharmaceutical Industries: Similar to Teva, Sun Pharma's vertically integrated operations include the production of FDFs.
• Major Generic Pharmaceutical Companies: Numerous other generic drug manufacturers, including but not limited to Mylan (now Viatris), Sandoz (a Novartis division), and Aurobindo Pharma, produce and market Estazolam tablets in various markets. The availability of these generic versions contributes to market competition and pricing dynamics.

The FDF manufacturing process is subject to rigorous quality assurance and regulatory oversight. Batch consistency, dissolution profiles, and stability are key parameters monitored throughout production.

WHAT ARE THE KEY REGULATORY CONSIDERATIONS FOR ESTAZOLAM MANUFACTURING AND SUPPLY?

Estazolam is classified as a Schedule IV controlled substance under the U.S. Controlled Substances Act due to its potential for abuse and dependence. This classification imposes specific regulatory requirements on its manufacturing, distribution, and prescribing.

• DEA Quotas: The U.S. Drug Enforcement Administration (DEA) sets annual aggregate production quotas for Schedule IV substances like Estazolam. These quotas limit the total amount of API that can be manufactured or imported into the U.S. each year. Manufacturers must apply for and adhere to these quotas.
• FDA Approval: All Estazolam products (API and FDF) must undergo FDA review and approval. This includes the submission of Drug Master Files (DMFs) for APIs and New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for finished products.
• GMP Compliance: Facilities involved in API and FDF manufacturing must maintain compliance with current Good Manufacturing Practices (cGMP). Regular inspections by regulatory authorities verify adherence to these standards.
• International Regulations: Manufacturers and suppliers operating globally must comply with the regulations of each country or region where the product is manufactured, imported, or sold. This includes adherence to EMA guidelines in Europe and similar regulatory frameworks in other jurisdictions.
• Controlled Substance Handling and Security: Strict security measures are required at all stages of the supply chain, from manufacturing to warehousing and distribution, to prevent diversion of controlled substances. This includes detailed record-keeping and reporting of all controlled substance transactions.

These regulations significantly influence the cost of production, lead times, and market entry for Estazolam suppliers. Compliance demands substantial investment in quality systems, security infrastructure, and regulatory affairs expertise.

WHAT ARE THE CURRENT MARKET DYNAMICS AFFECTING ESTAZOLAM SUPPLY?

The market for Estazolam is primarily driven by its status as a generic medication. The presence of multiple manufacturers leads to competitive pricing and influences supply availability.

• Generic Competition: The U.S. market for Estazolam has been dominated by generic competition since the patent expiry of the innovator drug. This has resulted in significant price erosion and a focus on cost-effective manufacturing for suppliers.
• API Sourcing: Pharmaceutical companies often source Estazolam API from global suppliers, particularly from countries with lower manufacturing costs, such as India and China. However, the stringent regulatory requirements and quota limitations in the U.S. can influence sourcing decisions.
• Supply Chain Vulnerabilities: Like many pharmaceutical supply chains, Estazolam production can be susceptible to disruptions. These can arise from raw material shortages, manufacturing issues at a key supplier, or regulatory actions impacting a production facility. The controlled substance status can further complicate resourcing if a primary API supplier faces regulatory challenges.
• Demand: While Estazolam is prescribed for insomnia, its usage may be influenced by the availability and prescribing patterns of newer or alternative insomnia treatments, including non-benzodiazepine hypnotics and sleep hygiene education. However, its established efficacy and cost-effectiveness as a generic option maintain a consistent demand base.
• DEA Quota Allocations: Changes in DEA annual aggregate production quotas can directly impact the available supply of Estazolam API in the U.S. Manufacturers must carefully plan their production based on these allocations.

The market is characterized by a balance between the need for reliable, high-quality supply and the imperative to maintain competitive pricing, all within a tightly regulated framework.

WHAT ARE POTENTIAL CHALLENGES AND OPPORTUNITIES FOR ESTAZOLAM SUPPLIERS?

Suppliers of Estazolam face a complex operating environment with both inherent challenges and potential avenues for growth or differentiation.

CHALLENGES

• Regulatory Scrutiny: The controlled substance status of Estazolam means suppliers are under constant regulatory scrutiny from agencies like the DEA and FDA. Non-compliance can lead to severe penalties, including manufacturing suspensions and product recalls.
• Pricing Pressure: The highly competitive generic market exerts significant downward pressure on pricing. Suppliers must achieve high manufacturing efficiencies to remain profitable.
• Quota Limitations: DEA aggregate production quotas can restrict the volume of Estazolam that can be produced, potentially limiting market share growth or creating supply constraints if demand exceeds quota allocations.
• Global Supply Chain Risks: Reliance on international sourcing for raw materials or intermediates can expose suppliers to geopolitical instability, trade disputes, or quality control issues in foreign manufacturing sites.
• Environmental, Social, and Governance (ESG) Standards: Increasing expectations for sustainable and ethical manufacturing practices require investment in greener processes and transparent supply chains.

OPPORTUNITIES

• Vertical Integration: Companies that can manage both API synthesis and FDF manufacturing offer greater control over their supply chain, potentially improving efficiency and reliability.
• Supply Chain Security and Redundancy: Demonstrating robust quality control, secure handling of controlled substances, and the establishment of redundant manufacturing sites or sourcing partners can be a competitive advantage, particularly for customers prioritizing supply chain resilience.
• Market Access in Emerging Economies: While the U.S. and European markets are mature, there may be opportunities in developing countries where access to affordable insomnia treatments is increasing. However, navigating diverse regulatory landscapes is critical.
• Specialty Chemical Synthesis Expertise: For API manufacturers, developing expertise in complex benzodiazepine synthesis can position them as preferred suppliers for pharmaceutical companies seeking reliable, high-quality ingredients.
• Focus on GMP Excellence: Maintaining impeccable GMP compliance and a strong regulatory track record can build trust with pharmaceutical partners and differentiate suppliers in a crowded market.

Successful suppliers will need to navigate these factors by focusing on operational excellence, robust quality systems, strategic sourcing, and proactive regulatory engagement.

KEY TAKEAWAYS

• Estazolam API production is primarily handled by specialized chemical manufacturers including Teva Pharmaceutical Industries, Accord Healthcare, Sun Pharmaceutical Industries, and Amneal Pharmaceuticals.
• Finished dosage form manufacturing is undertaken by generic drug companies such as Teva, Sun Pharma, and a broader range of pharmaceutical firms including Viatris and Sandoz.
• Regulatory oversight by the DEA and FDA, including controlled substance quotas and GMP compliance, critically shapes the manufacturing and supply of Estazolam.
• The Estazolam market is characterized by intense generic competition, global API sourcing, and potential supply chain vulnerabilities, necessitating a focus on cost-efficiency and reliability.
• Suppliers face challenges from pricing pressure and regulatory scrutiny but can leverage opportunities in vertical integration, supply chain security, and market access.

FAQS

1. What is the primary therapeutic indication for Estazolam? Estazolam is prescribed for the short-term treatment of insomnia.

2. How does the U.S. DEA regulate Estazolam manufacturing? The DEA regulates Estazolam as a Schedule IV controlled substance by setting annual aggregate production quotas to limit the total amount that can be manufactured or imported into the U.S.

3. Are there any significant differences in the manufacturing processes for Estazolam API versus finished dosage forms? Yes, API manufacturing involves complex chemical synthesis, while FDF production involves formulating the API with excipients into tablets and packaging. Both require strict GMP adherence.

4. What is the typical form of Estazolam available to patients? Estazolam is most commonly available in oral tablet form.

5. Can a single company manufacture both Estazolam API and the finished tablets? Yes, some vertically integrated pharmaceutical companies, such as Teva and Sun Pharma, are capable of both API synthesis and the manufacturing of finished dosage forms of Estazolam.

CITATIONS

[1] Drug Enforcement Administration. (2023). Controlled Substances Act. U.S. Department of Justice. [2] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). [3] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). [4] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. [5] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP).